filgrastim
information and resources from the National Cancer Institute
filgrastim
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. filgrastim
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions.
Neupogen Amgen, Inc Feb 20 1991
Neupogen
NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation hemotherapy treatment of adults with AML.
Amgen, Inc Apr 02 1998
Neupogen
NEUPOGEN is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever.
Amgen, Inc Apr 02 1998
Neupogen
NEUPOGEN is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation.
Amgen, Inc Apr 02 1998
|
|
|
|
news articles
[an error occurred while processing this directive][an error occurred while processing this directive] |
|
